The U.S. FDA has granted 510(k) clearance to MammoScreen™, the artificial intelligence (AI)-based software assisting radiologists in reading screening mammograms.
“Receiving FDA clearance for MammoScreen is a major milestone for Therapixel,” says Pierre Fillard, founder and chief scientific officer of Paris-based Therapixel. “This is the result of our collaboration with radiologists over the last three years to turn the algorithm that won the DREAM challenge in 2017 into a powerful product that is truly meaningful to their day-to-day-work.”
MammoScreen automatically detects and characterizes suspicious soft tissue lesions and calcifications in mammogram images while assessing their likelihood of malignancy. The results are presented in a summary report that characterized suspiciousness of each lesion scored on a scale of 1-10, with 1, being least likely to reveal malignancy and 10 most likely.
“We believe MammoScreen will provide quick and reliable confirmation of radiologists’ suspicions as they read,” says Matthieu Leclerc-Chalvet, Therapixel CEO. “This AI solution will ensure a more certain assessment by radiologists and a speedier reassurance of women having breast cancer screening exams, resulting in a more efficient workflow and reduced costs for the healthcare system. We look forward to installing MammoScreen in radiology departments and institutions across the U.S. so imaging professionals and women can benefit from its use.”
